E.E. Geduld’s Acadia Pharmaceuticals ACAD Stock Holding History

E.E. Geduld’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,000	Closed	-$325K	–	191
2016 Q2	$325K	Buy	+10,000	New	+$335K	0.43%	44
2013 Q4	–	Sell	-10,000	Closed	-$275K	–	317
2013 Q3	$275K	Hold	10,000	–	–	0.17%	145
2013 Q2	$182K	Buy	+10,000	New	+$138K	0.13%	163

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

E.E. Geduld's ACAD Position: Q4 2016 in Review

E.E. Geduld increased its Acadia Pharmaceuticals (ACAD) stake by 141% in Q4 2016, buying an estimated $403K and bringing the position to 26,000 shares worth $750K. The position accounts for 0.42% of the portfolio, ranked #25.

E.E. Geduld first reported a position in ACAD in Q2 2013 and has held it in 14 quarters since. The position peaked at $2.2M in Q3 2013. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

E.E. Geduld held 26,000 shares of Acadia Pharmaceuticals worth $750K as of Q4 2016.
E.E. Geduld bought 15,215 Acadia Pharmaceuticals shares in Q4 2016, an estimated $403K.
Acadia Pharmaceuticals made up 0.42% of E.E. Geduld's portfolio in Q4 2016, its #25 holding.
E.E. Geduld first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
E.E. Geduld's Acadia Pharmaceuticals position peaked at $2.2M in Q3 2013.
225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.